The funding brings Nestle’s total investment to $473 million, increasing the Swiss company’s stake to 19.9% of Aimmune’s outstanding stock and voting power. Nestle’s investment is an incremental positive for Aimmune’s shares, which have seen some weakness due to investor worries over financing, Piper Sandler analyst Christopher Raymond wrote in a note. “With this additional investment, we think the prospect of an outright take out by Nestle (or anyone else for that matter) has to be factored in more than before,” Raymond said. …read more
Source:: Yahoo Finance
